The global PEGylated drugs market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all players competing to gain presence in the market. Intense competition, rapid advances in technology, frequent changes in government policies, and regulations are key factors that confront market growth. The manufacturers compete based on cost, quality, and reliability. It is decisive for manufacturers to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, manufacturers should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional, and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.
Amgen, Inc., UCB S.A., Hoffmann-La Roche AG, Pfizer Inc., and Horizon Therapeutics PLC are the major player in the global PEGylated drugs market.
Amgen, Inc. is a US-based leading manufacturer of pharmaceutical products and accounted for 48.2% of the global PEGylated drugs market share in 2018. The company develops Neulasta, the most prescribed PEGylated drug by healthcare professionals. The company is focused on providing therapeutic products and services to humans through its innovating medicines based on advances in cellular and molecular biology. The company operates in various regions such as in the Americas, Asia-Pacific, and the rest of the world.
UCB S.A. accounted for the second-largest market share of 17.3% in 2018. The company manufactures, sells, and distributes biopharmaceutical solutions. The company has a robust drug pipeline and has filed its two molecules for approval. For instance, in March 2019, UCB S.A. received the US Food and Drug Administration approval for Cimzia (certolizumab pegol) injection for the treatment of a certain type of inflammatory arthritis such as non-radiographic axial spondyloarthritis (nr-axSpA).
Hoffmann-La Roche AG develops and markets products for the diagnosis and treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, and others. The company has a presence in more than 100 countries. It has a strong research and development department. The company develops two major PEGylated drugs, which are Pegasys and Mircera. Hoffmann-La Roche AG holds 6.8% in the global PEGylated drugs market.
Pfizer Inc. manufactures a wide range of medicines and vaccines in the field of immunology, oncology, cardiology, diabetology/endocrinology, and neurology. It focuses on acquisitions and collaboration strategies to expand its operational and geographical presence. For instance, in July 2019, Pfizer acquired Array BioPharma Inc., a US-based company. This acquisition has strengthened Pfizer’s biopharmaceutical and oncology business. Pfizer Inc. holds 3.3% in the global PEGylated drugs market.
Horizon Therapeutics PLC has products catering to a wide range of indications such as rheumatology, inflammation, and others. The company has different molecules in the pipeline, which provides it a potential business growth. Horizon Therapeutics PLC initiated a clinical trial evaluating Krystexxa (pegloticase injection) in combination with methotrexate for the treatment of uncontrolled gout.
Apart from these companies, there is a large number of companies operating in the global PEGylated drugs market. Some of these companies include Novo Nordisk A/S, AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG.
Michael Porter's Five Forces model is a framework to study the global PEGylated drugs market. Strategic business managers trying to gain an edge over competing firms in the global PEGylated drugs market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the Global PEGylated drugs market have been broken down and analysed.
PORTER'S FIVE FORCES ANALYSIs: Global PEGylated drugs market
Threat of New Entrants
The threat of new entrants in the global PEGylated drugs market is relatively moderate to low. This is due to significant barriers to entry, including the high capital investment required for research and development, advanced technological capabilities, and the complex regulatory approvals that must be met before drugs can enter the market. Additionally, the development of PEGylated drugs requires specialized knowledge of biotechnology and the production process, which further limits the ability of new players to compete effectively. Established companies with strong patents, large-scale production capabilities, and brand recognition have a considerable advantage, making it difficult for new entrants to gain market share.
BARGAINING POWER OF SUPPLIERS
In the PEGylated drugs market, the bargaining power of suppliers is moderate. While the production of PEGylated drugs requires specific materials such as polyethylene glycol (PEG) and specialized enzymes or conjugates, these ingredients are produced by several suppliers around the world. This creates some flexibility for drug manufacturers to source from multiple suppliers, limiting the influence of any single supplier. However, the need for high-quality, consistent supplies and the complexity of producing PEGylated compounds means that suppliers with expertise in this area may hold more negotiating power, especially if they provide unique or superior-grade materials.
Threat of Substitutes
The threat of substitutes in the global PEGylated drugs market is moderate. While PEGylated drugs offer notable advantages, such as improved pharmacokinetics and reduced immunogenicity, they are not without competition. Traditional non-PEGylated drugs and biologics are alternatives that can serve similar therapeutic purposes. Moreover, the increasing development of biosimilars, which are biologic medical products highly similar to already approved reference biologics, poses a potential substitute threat. However, the unique benefits of PEGylation, such as prolonged drug half-life and reduced frequency of administration, make substitutes less attractive, especially in treatments for chronic diseases and cancers.
Bargaining Power of Buyers
The bargaining power of buyers in the PEGylated drugs market is high. Buyers, including healthcare providers, insurers, and patients, have significant negotiating power due to the increasing availability of alternative treatment options and the growing presence of generic and biosimilar alternatives. The rising cost of healthcare and the pressure to reduce drug expenditures have led buyers to demand better pricing, discounts, and cost-effective alternatives. This has been further exacerbated by the increasing awareness and competition from generic and biosimilar companies, which provide lower-cost options for the same therapeutic effect. As such, buyers have more influence in driving down prices and seeking better value in their drug purchases.
Intensity of Rivalry
The intensity of rivalry in the global PEGylated drugs market is high. This is due to the presence of numerous well-established pharmaceutical companies competing for market share, as well as the increasing number of new drug launches and developments in PEGylation technologies. Additionally, the market is pressured by the growing number of biosimilars and generics, which intensify price competition. Companies are constantly innovating to improve their PEGylated drugs' efficacy, safety, and patient compliance to differentiate themselves in the market. As the market matures and more treatments become available, competition for leadership in this segment continues to escalate, leading to aggressive marketing strategies and significant pricing pressures.
Impact of covid-19 on the Global PEGylated drugs market
Impact of COVID-19 on the Global PEGylated Drugs Market
The COVID-19 pandemic, while challenging, has also highlighted the resilience and importance of the global PEGylated drugs market, driving both innovation and opportunities for growth. The pandemic’s influence was multifaceted, affecting supply chains, clinical trials, research and development (R&D) activities, and healthcare systems. However, despite the disruptions, it also fostered new perspectives and advancements that continue to shape the future of PEGylated drug therapies.
Adapting Supply Chains and Enhancing Production Flexibility
The global pandemic emphasized the need for resilient and adaptable supply chains in the pharmaceutical industry. While there were initial disruptions due to lockdowns and restrictions, manufacturers and suppliers rapidly adapted by exploring new strategies to enhance production flexibility. Efforts were made to secure a continuous supply of critical materials, including polyethylene glycol (PEG) and other specialized components used in PEGylated drug development. This adaptability has strengthened the foundation for future growth, ensuring that manufacturers are better equipped for any challenges that may arise.
Clinical Trials and Research: A Resilient Recovery
Although clinical trials and research were temporarily impacted by the pandemic, the sector demonstrated remarkable resilience. As healthcare priorities shifted, many clinical trials for PEGylated drug candidates resumed once restrictions eased, and the pace of research has since accelerated. The adoption of digital technologies, remote monitoring, and innovative approaches to patient recruitment is expected to create more efficient pathways for conducting trials and bringing new PEGylated therapies to market in the future.
Surge in Demand for PEGylated Drugs in Chronic Disease Management
Amidst the pandemic, the demand for PEGylated drugs remained robust, particularly for patients with chronic conditions requiring ongoing care. These drugs are essential in the treatment of cancer, autoimmune diseases, and chronic kidney disease. Despite the pressures on healthcare systems, the ongoing need for these therapies underscored the significance of PEGylated drugs in managing long-term health conditions. This consistent demand, especially in oncology and chronic disease management, not only stabilized the market but also highlighted the critical role of PEGylated therapies in patient care.
Increased Focus on Innovation and Regulatory Flexibility
The pandemic also accelerated the adoption of new technologies and innovative therapies, particularly in the realm of vaccines and long-acting treatments. Regulatory bodies, while managing the urgent needs surrounding COVID-19, maintained a focus on encouraging innovation. The global shift towards mRNA technology has opened up new opportunities for PEGylation in enhancing vaccine efficacy and extending therapeutic half-lives. This has led to renewed interest in PEGylated therapies, particularly as the technology proves effective in enhancing the delivery and duration of various treatments.
Launches that Boosted the Market During COVID-19
The COVID-19 pandemic accelerated the development and introduction of groundbreaking vaccines, including PEGylated components, which played a key role in boosting the market for PEGylated drugs.
